Bromodomain and extra-terminal domain inhibition modulates the expression of pathologically relevant microRNAs in diffuse large B-cell lymphoma

  title={Bromodomain and extra-terminal domain inhibition modulates the expression of pathologically relevant microRNAs in diffuse large B-cell lymphoma},
  author={Afua Adjeiwaa Mensah and Luciano Cascione and Eugenio Gaudio and Chiara Tarantelli and Riccardo Bomben and Elena Bernasconi and Domenico Zito and Andrea Lampis and Jens Claus Hahne and Andrea Rinaldi and Anastasios Stathis and Emanuele Zucca and Ivo Kwee and Valter Gattei and Nicola Valeri and Mar{\'i}a Eugenia Riveiro and F. Bertoni},
  pages={2049 - 2058}
Aberrant changes in microRNA expression contribute to lymphomagenesis. Bromodomain and extra-terminal domain inhibitors such as OTX015 (MK-8628, birabresib) have demonstrated preclinical and clinical activity in hematologic tumors. MicroRNA profiling of diffuse large B-cell lymphoma cells treated with OTX015 revealed changes in the expression levels of a limited number of microRNAs, including miR-92a-1-5p, miR-21-3p, miR-155-5p and miR-96-5p. Analysis of publicly available chromatin… 

Figures and Tables from this paper

Bromodomain and Extraterminal Proteins as Novel Epigenetic Targets for Renal Diseases
Epigenetic mechanisms, especially DNA methylation and histone modifications, are dynamic processes that regulate the gene expression transcriptional program in normal and diseased states. The
Bromodomain and Extra-Terminal domain inhibitors for lymphoid malignancies.
There are now plenty of preclinical data sustaining BET proteins as therapeutic targets in lymphomas, and newer compounds and combinations with other agents may be pursued in the future aiming also to identify those patients that they most likely benefit from BET inhibition.
Characterization of GECPAR, a noncoding RNA that regulates the transcriptional program of diffuse large B-cell lymphoma
The tumor suppressor activity of GECPAR is demonstrated, which is mediated via its transcriptional regulation of proliferation and differentiation genes, particularly MYC and the Wnt pathway.
A Phase 1 study of RO6870810, a novel bromodomain and extra-terminal protein inhibitor, in patients with NUT carcinoma, other solid tumours, or diffuse large B-cell lymphoma.
Responses in patients with NC, other solid tumours and DLBCL provide proof-of-principle for BET inhibition in MYC-driven cancers and support further exploration of RO6870810 as monotherapy and in combinations.
RAS Mediates BET Inhibitor-Endued Repression of Lymphoma Migration and Prognosticates a Novel Proteomics-Based Subgroup of DLBCL through Its Negative Regulator IQGAP3
It is found that BET inhibitor JQ1 abrogated the amoeboid movement of DLBCL cells through a small GTPase-driven mechanism, including both restrained RAS signaling and MYC-mediated suppression of GTP-RhoA activity.
Upregulated miR-96-5p inhibits cell proliferation by targeting HBEGF in T-cell acute lymphoblastic leukemia cell line.
The presented study showed that upregulation of miR-96-5p inhibited the viability and proliferation of Jurkat T-leukemic cells through suppressing HBEGF expression, a novel sight for understanding the pathological mechanism of T-ALL.
Modulation of macrophage inflammatory function through selective inhibition of the epigenetic reader protein SP140
The discovery of the first small molecule SP140 inhibitor (GSK761) is reported and utilized to elucidate SP140 function in innate immune cells and identify SP140 as a druggable epigenetic reader and therapeutic target for CD.
Small Molecules Targeting HATs, HDACs, and BRDs in Cancer Therapy
This review will focus on summarizing the changes of histone acetylation levels during tumorigenesis, as well as the possible pharmacological mechanisms of small molecules that target histoneacetylation in cancer treatment.


The BET Bromodomain Inhibitor OTX015 Affects Pathogenetic Pathways in Preclinical B-cell Tumor Models and Synergizes with Targeted Drugs
In vitro and in vivo experiments showed that OTX015 targeted NFKB/TLR/JAK/STAT signaling pathways, MYC- and E2F1-regulated genes, cell-cycle regulation, and chromatin structure, and the compound induced apoptosis in a genetically defined subgroup of cells.
Targeting bromodomains: epigenetic readers of lysine acetylation
Recent progress in the development of bromodomain inhibitors is highlighted, and their potential applications in drug discovery are highlighted.
Abstract C244: Development of the BET bromodomain inhibitor OTX015.
Introduction: The BET bromodomain proteins, including BRD2, BRD3, and BRD4, have emerged as major epigenetic regulators of proliferation and differentiation and also have been associated with
Selective inhibition of protein arginine methyltransferase 5 blocks initiation and maintenance of B-cell transformation.
It is concluded that PRMT5 is critical to EBV-driven B-cell transformation and maintenance of the malignant phenotype, and thatPRMT5 inhibition shows promise as a novel therapeutic approach for B- cell lymphomas.
MicroRNA 96 is a post-transcriptional suppressor of anaplastic lymphoma kinase expression.
Blockade of oncogenic IκB kinase activity in diffuse large B-cell lymphoma by bromodomain and extraterminal domain protein inhibitors
It is reported that genetic or pharmacologic interference with bromodomain and extraterminal domain (BET) chromatin proteins reduces NF-κB activity and ABC DLBCL viability, and provides a mechanistic basis for the clinical development of BET protein inhibitors in ABCDLBCL, particularly in combination with other modulators of oncogenic IKK signaling.
The MYC/miR-17-92 axis in lymphoproliferative disorders: A common pathway with therapeutic potential
The role of the miR-17-92 cluster in lymphoproliferative disorders, including diagnostic/prognostic implications, and on the potential applications of anti-miRNAs based therapies targeting miRNAs belonging to the cluster are focused on.
Clinical Response of Carcinomas Harboring the BRD4-NUT Oncoprotein to the Targeted Bromodomain Inhibitor OTX015/MK-8628.
The first clinical proof-of-concept that targeting BRD4-NUT with a BET inhibitor results in impressive and rapid antitumor activity in NMC is presented, offering strong potential for future clinical application in this rare patient population as either a single agent or in combination with other agents.